We back visionary founders who challenge the status quo to transform women’s health and build healthier communities for us all.
Our portfolio companies drive change across a range of sectors—from life sciences and digital health to services—innovative solutions that address women’s unique health challenges. Together, we’re forging a new future of healthcare, creating lasting impact, and improving lives for generations to come.
Revolutionizing maternal health through data-driven solutions and remote prenatal care.
Mobilizing the power of the community and technology to deliver personalized, home-based maternity care for underserved communities.
Launching a new era of contraception through human-centered design and harnessing the natural barrier properties of cervical mucus.
Inventing the future of male contraception with the first long-lasting, reversible implant solution for men.
Making continuous hormone monitoring possible by bringing the first at-home technology, giving you real time insights from the hormones in your saliva.
Delivering at-home vaginal microbiome tests designed to close the gender health gap and improve female health.
Redesigning maternity care with holistic, tech-enabled, midwife-led pregnancy care.
Medical device company dedicated to improving pregnancy outcomes and reducing the risk of preterm birth.
Providing telehealth and online pharmacy services with Thirty Madison’s reproductive and sexual health brand.
Transforming episodic care into continuous support across fertility, maternity and parenting with a digital health platform.
Providing insurance-covered specialized therapy and community support for perinatal mental health conditions.
Providing results, at home, in minutes through tech-enabled sexually-transmitted infection (STI) self-testing kits.
Bringing equity to sexual and reproductive health by increasing access, convenience and affordability through telehealth and online pharmacy.
Building the family planning company of the 21st century with novel non-hormonal contraceptives for men and women.
Foreground Capital has built one of the world’s largest dedicated women’s health portfolio investing in early-stage companies that make care more accessible, affordable, and equitable.
Copyright© 2024 FOREGROUND CAPITAL, All rights reserved | Privacy Policy
Alice Zheng, MD
Partner
Alice Zheng has been a women’s health enthusiast throughout her career spanning global health, clinical medicine, and the private sector. She is currently a Co-founder and Partner at Foreground Capital. Previously, she was a Principal at Foreground’s precursor funds at RH Capital. At Foreground Capital, she continues to manage RH Capital funds and serves as a board director for Seven Starling and Millie and as a board observer for AOA and Eli Health.
Previously, Alice was a women’s health practice leader and management consultant at McKinsey & Company, where she published foundational research on women’s health. Earlier in her career, she trained as a physician with a focus on women’s health and worked in global public health in East Africa and Asia. She has also been a patient in many women’s health areas including infertility, abortion, and difficult pregnancies.
Alice holds an MBA from Harvard Business School and MD/MPH from the University of Michigan, where she was a Dean’s Merit Scholar. Her profile has been featured in Business Insider, 30 under 40 Healthcare, Michigan Medicine and more. She holds advising and mentoring roles with multiple women’s health accelerators and forums, including co-chair of the NYSE Women’s Health Summit, which was headlined by First Lady Dr. Jill Biden in 2024.
Why women’s health?
“I’ve always been drawn to underserved women’s issues, from performing in the Vagina Monologues three times in college to working in rural African villages without running water or electricity to prevent and treat obstetric fistulas. I am now a mother of two and have been a patient myself in many women’s health areas I once aspired to specialize in. It is a long-standing personal and professional passion of mine to improve lives of women around the world.”
Stasia Obremskey
Managing Partner
Stasia Obremskey has been investing in women for her entire career, believing that the two most impactful things you can do for the world are to educate women and give them tools to manage their fertility. She is currently a Co-founder and Managing Partner at Foreground Capital. Stasia co-founded and led Foreground’s precursor funds at RH Capital. At Foreground Capital, she continues to manage RH Capital funds and serves as a board director for Cadence OTC and as a board observer for Vitra Labs, Contraline, Eli Health and YourChoice Therapeutics.
Previously, Stasia worked with healthcare organizations in the US and Asia, where she joined management teams as the Chief Financial Officer to provide finance, accounting, and strategic planning expertise to startups, fast-growing companies, and non-profit organizations. She began her career in management consulting with Bain & Company and investment banking with Morgan Stanley & Co.
She holds an MBA from Harvard Business School and holds a bachelor’s degree in Business Administration with a concentration in finance from the University of Notre Dame. In addition to her consulting work, she has extensive experience as a member of several nonprofit boards.
Why women’s health?
“While women make up 50% of the population, they birth 100% of the population and yet their unique healthcare needs have been historically overlooked. I’m passionate about finding innovations to reverse this trend and address the many areas in women’s health still looking for improved and new solutions.”
Elizabeth Bailey
Managing Partner
Elizabeth Bailey has over 20 years of experience in venture capital and supporting early-stage healthcare companies. She is currently a Co-founder and Managing Partner at Foreground Capital. Elizabeth co-founded and led Foreground’s precursor funds at RH Capital. At Foreground Capital, she continues to manage RH Capital funds and serves as a board director for Raydiant Oximetry and Testmate Health, and as a board observer for Bloomlife, Cayaba, Mae and Twentyeight Health.
Elizabeth was previously a Partner at Commons Capital, one of the first impact investment funds, where she managed the healthcare portfolio, including Claros Diagnostics (acquired by OPKO), CodeRyte (acquired by 3M), HistoRx (acquired by Genoptix), Medical Metrx Solutions (acquired by AIG) and TelaDoc (IPO: TDOC).
She holds a Masters in Public Policy from Harvard Kennedy School and a BA from Brown University. Throughout her career, Elizabeth has been a strong advocate of the power of business to drive social change. In 2023, she was named a Trailblazing Leader in Women’s Health, and in 2024 Elizabeth received the inaugural FemForce Vanguard Award for her leadership in women’s health.
Why women’s health?
I think Maya Angelou said it best, “I’m interested in women’s health because I’m a woman. I’d be a darn fool not to be on my own side.”
